Relief Therapeutics Holding AG (RLFTF)

[DrC94]

“Admittedly, if the “COVID-AIV” trial demonstrated similar strong efficacy signals during the Data Monitoring Committee interim analyses as seen in the EAP trial, the trial would have been stopped early and filed for US Emergency Use Authorization.
However, patients in the phase IIb/III are not as critically ill as those in the EAP. The drug’s impact may be most evident in the sickest patients.”